Top

Published in:

01-03-2005 | Review

New developments in ochronosis: review of the literature

Authors: Julie M. Keller, William Macaulay, Ohannes A. Nercessian, Israeli A. Jaffe

Published in: Rheumatology International | Issue 2/2005

Abstract

Ochronosis commonly affects all connective tissue. Recognition of changes secondary to the deposition of ochronotic pigments has increased with advances in diagnostic technology, allowing both improved imaging and early biochemical and genetics-based diagnosis of alkaptonuria, the cause of ochronosis. Successful symptomatic treatment of ochronotic arthropathy with joint replacement has been documented, and a new pharmacotherapeutic agent, nitisinone, is currently under investigation for both prevention and treatment of ochronosis. This review of the literature highlights recently recognized complications, new diagnostic techniques, and treatment options.

Selvi E, Manganelli S, Benucci M, Marcolongo R (2000) Chronic ochronotic arthritis: clinical, arthroscopic and pathologic findings. J Rheumatol 27:2272–4PubMed

Sahin G, Milcan A, Bagis S, Kokturk A, Pata C, Erdogan C (2001) A case of ochronosis: upper extremity involvement. Rheumatol Int 21:78–80CrossRefPubMed

Kumar RV, Rajasekaran S (2003) Spontaneous tendon ruptures in alkaptonuria. J Bone Joint Surg Br 85:883–6PubMed

Farzannia A, Shokouhi G, Hadidchi S (2003) Alkaptonuria and lumbar disc herniation. J Neurosurg (Spine 1) 98:87–9

Hamdi N, Cooke TDV, Hassan B (1999) Ochronotic arthropathy: case report and review of the literature. Int Orthop 23:122–5CrossRefPubMed

Laskar FH, Sargison KD (1970) Ochronotic arthropathy: a review with four case reports. J Bone Joint Surg Br 52:653–65PubMed

Ellaway CJ, Holme E, Standing S, Preece MA, Green A, Ploechl E et al (2001) Outcome of tyrosinemia type III. J Inher Metab Dis 24:824–32CrossRefPubMed

La Du B (2002) Alkaptonuria. In: Royce RM, Steinman B (eds) Connective tissue and its heritable disorders: molecular, genetic and medical aspects. Second edn. Wiley-Liss, New York, pp 809–825

Aydogdu S, Cullu E, Ozsoy MH, Sur H (2000) Cementless total knee arthroplasty in ochronotic arthropathy: a case report with 4-year follow-up. J Arthroplasty 15:539–43CrossRefPubMed

10.

Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL et al (2002) Natural history of alkaptonuria. N Engl J Med 347:2111–21CrossRefPubMed

11.

Nas K, Gur A, Akdeniz S, Cevik R, Harman M, Sarac AJ (2002) Ochronosis: a case of severe ochronotic arthropathy. Clin Rheumatol 21:170–2CrossRefPubMed

12.

Alrehaily A, Pope JE (2002) Alkaptonuria with atypical joint involvement. J Rheumatol 29:198–9PubMed

13.

MacKenzie CR, Major P, Hunter T (1982) Tendon involvement in a case of ochronosis. J Rheumatol 9:634–6PubMed

14.

Seradge H (1981) Ochronotic stenosing flexor tenosynovitis. J Hand Surg 6:359–60

15.

Uyguner O, Goicoechea de Jorge E, Cefle A, Baykal T, Kayserili H, Cefle K, Demirkol M, Yuksel-Apak M, Rodriguez de Cordoba S, Wollnik B (2003) Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58 fs mutation originated from central Asia and was spread throughout Europe and Anatolia by human migrations. J Inherit Metab Dis 26:17–23CrossRefPubMed

16.

Zatkova A, Chmelikova A, Polakova H, Ferakova E, Kadasi L (2003) Rapid detection methods for five HGO gene mutations causing alkaptonuria. Clin Genet 63:145–9PubMed

17.

Aliberti G, Pulignano I, Schiappoli A, Minisola S, Romagnoli E, Proietta M (2003) Bone metabolism in ochronotic patients. J Int Med 254:296–300CrossRef

18.

Borman P, Bodur H, Ciliz D (2002) Ochronotic arthropathy. Rheumatol Int 21:205–9CrossRefPubMed

19.

Carrier DA, Harris CM (1990) Bilateral hip and bilateral knee arthroplasties in a patient with ochronotic arthropathy. Orthop Rev 19:1005–9PubMed

20.

Suzuki Y, Oda K, Yoshikawa Y, Maeda T, Suzuki T (1999) A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 44:79–84CrossRefPubMed

21.

Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM et al (1998) From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTMC), its toxicology and development as a drug. J Inher Metab Dis 21:498–506CrossRefPubMed

22.

Beighton P (1993) Alkaptonuria. McKusick’s heritable disorders of connective tissue. Fourth edn. Mosby, St. Louis, pp 315–30

Title: New developments in ochronosis: review of the literature
Authors: Julie M. Keller
William Macaulay
Ohannes A. Nercessian
Israeli A. Jaffe
Publication date: 01-03-2005
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 2/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-004-0498-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

New developments in ochronosis: review of the literature

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2005

Glucocorticoid iontophoresis for Achilles tendon enthesitis in ankylosing spondylitis: significant response documented by power Doppler ultrasound

The German Short Musculoskeletal Function Assessment questionnaire: reliability, validity, responsiveness, and comparison with the Short Form 36 and Constant score—a prospective evaluation of patients undergoing repair for rotator cuff tear

Immunohistochemical analysis of transforming growth factor beta isoforms and their receptors in human cartilage from normal and osteoarthritic femoral heads

Kikuchi’s disease involving the supraclavicular lymph nodes and associated with transient eruption

Protein-losing enteropathy associated with systemic lupus erythematosus: response to cyclophosphamide

Unusual presentation of lupus nephritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page